NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00626990,Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH),https://clinicaltrials.gov/study/NCT00626990,CATNON,ACTIVE_NOT_RECRUITING,"RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma.

PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.",YES,Brain and Central Nervous System Tumors,DRUG: temozolomide|GENETIC: DNA methylation analysis|OTHER: laboratory biomarker analysis|PROCEDURE: adjuvant therapy|PROCEDURE: quality-of-life assessment|RADIATION: radiation therapy,"Overall Survival as Measured From the Day of Randomization, The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination., from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)","Progression-free Survival, Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms., from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)|Quality of Life of the Patient, Quality of life was assessed by the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 and the Brain Cancer Module-20, from 14 days prior to randomization till five years or death (time till death is up to 10.9 years after patient enrollment in the study)|Neurological Deterioration Free Survival, Neurological deterioration is defined as a decrease in WHO performance status as follows:

decrease in WHO performance status

* for patients with baseline WHO performance status 0: deterioration to WHO performance status 2 or worse for which no other explanation is present, and which is maintained for at least three months
* for patients with baseline WHO performance status 1 or 2: deterioration to WHO performance status 3 or worse for which no other explanation is present and which is maintained for at least three months

The date of neurological deterioration will be the first date the persistent decrease in performance status was diagnosed. Neurological deterioration free progression is the time interval between the date of randomization and the date of neurological deterioration or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination, within 2 weeks of randomization; during radiotherapy at week 4 and 6; 4 weeks after the end of radiotherapy; Six monthly after the end of radiotherapy; Prior to each cycle of adjuvant therapy; Every six months after the documentation of first progression.",,European Organisation for Research and Treatment of Cancer - EORTC,NCIC Clinical Trials Group|Radiation Therapy Oncology Group|Medical Research Council|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,751,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EORTC-26053-22054|NCIC CTG CEC.1|RTOG-0834|2006-001533-17|P04839|MRC BR14,2007-12,2018-09-05,2029-12,2008-02-29,2023-09-11,2023-09-11,"Arizona Oncology Services Foundation, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF University of California San Francisco Medical Center-Mount Zion, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital, Fort Wayne, Indiana, United States|Saint Vincent Oncology Center, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, 50010, United States|June E. Nylen Cancer Center, Sioux City, Iowa, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Maine Medical Center, Scarborough, Maine, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachussets General Hospital Cancer Center, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|St John's Mercy Medical Center, Saint Louis, Missouri, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|State University of New York Upstate Medical University, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester - James P. Wilmot Cancer Center, Rochester, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Akron City Hospital - Summa Health System, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Western Reserve University, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Orange Village, Ohio, United States|Cancer Care Center, Incorporated, Salem, Ohio, United States|UHHS - Westlake Medical Center, Westlake, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|UPMC - Heritage Valley Health System - The Medical Center, Beaver, Pennsylvania, United States|Penn State M.S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital and Medical Center, West Reading, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Radiation Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|University of Texas Medical Branch, Galveston, Texas, United States|Md Anderson Cancer Center, Houston, Texas, United States|Methodist Hospital, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|University Of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Virginia Mason CCOP, Seattle, Washington, United States|Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|University Of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Royal North Shore Hospital, St. Leonards, New South Wales, 2065, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Flinders Medical Centre, Bedford Park, Australia|Austin-Repatriation Medical Centre, Heidelberg, Australia|Royal Hobart Hospital, Hobart, Australia|St Vincent'S Hospital, Melbourne, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Alfred Hospital, Prahran, Australia|ZNA Middelheim, Antwerpen, Belgium|Cliniques Universitaires St. Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Clinique Notre-Dame, Charleroi, Belgium|Algemeen Ziekenhuis Sint Lucas, Gent, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre, Calgary, Canada|London Regional Cancer Center, London, Canada|Allan Blair Cancer Centre, Saskatoon, Canada|University Health Network - Oci / Princess Margaret Hospital, Toronto, Canada|Cancercare Manitoba, Winnipeg, Canada|Assistance Publique - HÃ´pitaux de Marseille - C.H.U. De La Timone, Marseille, France|C.H.U. de Nancy - Hopital St Julien, Nancy, France|Centre Antoine Lacassagne, Nice, France|Chu Pitie-Salpetriere AP-HP, Paris, France|Centre Eugene Marquis, Rennes, France|Institut Gustave Roussy, Villejuif, France|Klinikum Bamberg, Bamberg, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Medizinische Hochschule Hannover, Hannover, Germany|UniversitaetsKlinikum Heidelberg, Heidelberg, Germany|Universitaetskliniken Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Ospedale Bellaria, Bologna, Italy|Istituto Scientifico H.S. Raffaele, Milano, Italy|Azienda Ospedaliera San Giovanni Battista Di Torino-Universita Di Torino, Torino, Italy|Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Maastro Clinic - Maastricht Radiation Oncology, Maastricht, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands|Hospital Clinic Universitari, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Barcelona, Spain|Hopital Cantonal Universitaire De Geneve, Geneve, Switzerland|Universitaetsspital, Zurich, Switzerland|University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Royal Devon And Exeter Hospital, Exeter, United Kingdom|St. James'S University Hospital, Leeds, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital campus, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|Clatterbridge Centre for Oncology NHS Trust, Wirral, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/90/NCT00626990/Prot_SAP_000.pdf"
